Other News

Methodist Le Bonheur Healthcare’s Olive Branch Hospital is Among Nation’s Top Performing Hospitals for Treatment of Heart Attack Patients

 American College of Cardiology recognizes sustained, high-level performance in quality of care MEMPHIS, Tenn., June 1, 2023 /PRNewswire/ — The American College of Cardiology recognizes Methodist Le Bonheur Healthcare‘s Olive Branch Hospital for its dedication and excellence in treating heart attack patients. Methodist Olive Branch Hospital received the National Cardiovascular Data Registry Chest Pain – […]

Penumbra Expands Computer-Aided Thrombectomy Offerings with Lightning Bolt 7 Technology Designed to Rapidly Remove Blood Clots with Modulated Aspiration

Lightning Bolt™ 7 is the most advanced arterial thrombectomy system on the market Latest technology combines modulated aspiration with superior catheter design to maximize blood clot removal in a single session ALAMEDA, Calif., June 1, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the U.S. Food […]

Fluid Biomed Inc. Announces World’s First Implantation of Polymer-based Neurovascular Stent in Human Patients

First-in-Human Clinical Safety Trial is Successfully Launched using ReSolv™, the Unique Polymer-Based Flow-Diverting Stent Designed to Treat Brain Aneurysms Company Advisory Board Expands to Include Respected Medical Key Opinion Leader and Medtech Entrepreneur CALGARY, AB, June 1, 2023 /PRNewswire/ – Fluid Biomed Inc., a medical device company developing ReSolv™, the world’s first hybrid […]

Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

– Submitted four efficacy supplements seeking inclusion of CV risk reduction and expansion of LDL-C lowering –  – Anticipated approvals in U.S. in the first half of 2024 –  ANN ARBOR, Mich., June 01, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that it has submitted Supplemental New Drug Applications (sNDA) to […]

Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension

Joshua Ziel, PhD, appointed as Chief Operating Officer and interim Chief Executive Officer Gary Burgess, MD, appointed as Chief Medical Officer Sarah Fritchley, PhD, appointed as Senior Vice President, Clinical Development and Operations DURHAM, N.C., June 01, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated […]

Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, June 01, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being […]

Lundquist Institute Investigators Co-Author Paper in JAMA on Coronary Heart Disease (CHD) Risk Prediction

Drs. Jerome Rotter & Matt Budoff Study Shows that in Middle-aged to Older Adults the Coronary Artery Calcium Score Improved CHD Risk Discrimination Los Angeles, June 01, 2023 (GLOBE NEWSWIRE) — The Lundquist Institute (TLI) announced today that Jerome Rotter, MD, and Matthew Budoff, MD, two of TLI’s investigators, are […]

Cleerly Partners with ProScan Imaging to Transform the Standard of Care for Heart Disease Prevention

ProScan’s imaging centers in two major regions will now leverage Cleerly’s AI-enabled approach to develop personalized heart care diagnoses and treatment plans DENVER – May 31, 2023 — Cleerly, the company creating a new standard of care for heart disease, announced today a partnership with ProScan Imaging to offer more personalized […]

Kardium Announces First US Procedures in PULSAR Study of Globe® Pulsed Field System

VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium Inc., a private medical device company that has developed the Globe System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today that the first US patients have been successfully treated in the PULSAR clinical study. The PULSAR study will enroll over 400 patients […]